RightFit
RecruitingPhase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 75 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests how well macupatide plus eloralintide helps adults with obesity or overweight lose weight and how safe it is. It compares the treatment with a placebo, a treatment with no active drug, in people without type 2 diabetes. The study lasts about 64 weeks.

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • See the main study plan, CWMM (NCT06143956), for the requirements to join.

Who can't join

  • Other reasons you cannot join are listed in the main study plan, CWMM (NCT06143956).
  • You have type 1 or type 2 diabetes.
  • You have an ongoing slow or slow, irregular heartbeat.
  • Your resting pulse is more than 100 or less than 60 beats per minute.
  • You have had pancreatitis, or swelling of the pancreas, either sudden or long-lasting.
  • Your other medicines have not stayed at the same dose for at least 3 months before screening.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * See Master Protocol CWMM (NCT06143956) for inclusion criteria Exclusion Criteria: In addition to exclusion criteria in Master Protocol CWMM (NCT06143956): * Have type 1 diabetes or type 2 diabetes * Have an ongoing history of bradyarrhythmia and/or sinus bradycardia * Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm) * Have a history of acute or chronic pancreatitis * All concomitant medications should be at a stable dose for at least 3 months prior to screening

Study sites (40)

AZ

  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa · Chandler, AZ 85225Yessica Sachdeva · Principal investigatorMore trials in Chandler
  • Headlands Research - Scottsdale · Scottsdale, AZ 85260Benjamin Clark · Principal investigatorMore trials in Scottsdale
  • The Institute for Liver Health II dba Arizona Liver Health-Tucson · Tucson, AZ 85712Anita Kohli · Principal investigatorMore trials in Tucson

CA

CT

FL

ID

  • Medical Research Partners · Ammon, ID 83406Joseph Moore · Principal investigatorMore trials in Ammon

IL

  • Great Lakes Clinical Trials - Ravenswood · Chicago, IL 60640Rupal Trivedi · Principal investigatorMore trials in Chicago

KS

  • Cotton O'Neil Diabetes & Endocrinology · Topeka, KS 66606susan brian · Principal investigatorMore trials in Topeka

KY

  • Monroe Biomedical Research - Louisville · Louisville, KY 40213Harold Bays · Principal investigatorMore trials in Louisville

MA

MI

  • Headlands Research - Detroit · Southfield, MI 48034Christopher Romero · Principal investigatorMore trials in Southfield
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division · Troy, MI 48098Neil Fraser · Principal investigatorMore trials in Troy

MO

NC

NV

NY

OH

SC

TN

TX

VA

  • Sovah Clinical Research-River District · Danville, VA 24541Stephan Jannach · Principal investigatorMore trials in Danville

WA

  • Central Washington Health Services Association d/b/a Confluence Health · Wenatchee, WA 98801Kathryn Eren · Principal investigatorMore trials in Wenatchee